Cytometric Therapeutics is advancing a new era of precision oncology by combining live-cell functional testing with translational research. Our mission is to develop therapies that target disease while respecting the individuality of each patient’s biology. We believe precision medicine should unite scientific accuracy with compassion and measurable results.
Doctors Larry Weisenthal and William Grace have collaborated for 38 years on testing anti-cancer drugs in the tissue cultures of actual cancer patients.
In pursuit of effective therapies, they discovered a new therapy with the goal of treatment to increase dramatically the effectiveness of standard chemotherapeutic agents.
The therapy has been tested on over a dozen types of cancer, and Cytometric Therapeutics is preparing for clinical trials this year.
Measures real tumor response, including cell death and resistance.
Evaluates both single agents and drug combinations.
Ranks therapies based on observed activity.
Supports repeat testing as disease evolves.
A wholly owned subsidiary of Cytometric Therapeutics, WCG provides the functional data that informs treatment selection and clinical development. CytoVantage 3D measures how living tumor cells respond to cancer therapies within intact cell clusters, preserving tumor biology and enabling direct observation of treatment response.
CTI Biopharma is the clinical development division of Cytometric Therapeutics. Testing and treatment identification occur within WCG Precision Therapy through CytoVantage 3D. CTI Biopharma advances selected combinations into defined therapies and clinical development.
Cytometric Therapeutics has secured $40 million in Series A funding. Led by Madison Dearborn Partners founder James N. Perry, this investment will accelerate its first clinical trial and expand laboratory operations in Huntington Beach, CA.
Read the Full Announcement →At Cytometric Therapeutics, we value collaboration and curiosity. Whether you’re a researcher, investor, clinician, or patient advocate, we welcome your interest in our work advancing next-generation cancer therapies.